Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (3001)	11/26/1997 1:14:00 AM
From: Pseudo Biologist	Read Replies (3) \| Respond to of 6136

Oliver &Co, thanks for posting this. It would be interesting to figure out how quickly (and how much) the virus is replicating in these resting T-cells. If, as I guess, the answer is not very; then the issue of resistance arising is fairly academic (as in, it would take 100's of years at these rates for the virus to hit on the right combination of mutations to generate resistance without rendering critical proteins - RT and protease - seriously deficient). Thanks also for your previous post on patient population size and Viracept market share. PB